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Regulator of telomere elongation helicase 1 (RTEL1) is a DNA helicase 
involved in telomere maintenance.1,2 Germline biallelic RTEL1 variants have been 
previously reported in a subset of patients with dyskeratosis congenita (DC) and its 
severe variant Hoyeraal-Hreidarsson syndrome (HH).3-6 Furthermore, germline 
heterozygous RTEL1 variants have been linked to a subset of patients with 
pulmonary fibrosis.2,7,8  We have undertaken sequencing analysis (whole exome and 
targeted9) of RTEL1, using genomic DNA extracted from peripheral blood of 429 
patients from our international bone marrow failure registry which includes DC, HH, 
aplastic anemia (AA), and familial myelodysplasia/leukemia (MDS/AML). This has 
revealed that 35 out of the 429 patients have RTEL1 variants (Table 1). Based on 
the minor allele frequency in the population reported on Exome Aggregation 
Consortium database (ExAC – http://exac.broadinstitute.org/), the type of variant 
(missense, nonsense and indels), telomere length, the Combined Annotation 
Depletion (CADD) score10, and segregation as well as information found in the 
literature, we classified these variants into four different groups: (1) biallelic variants, 
(2) heterozygous loss of function (LOF) variants, (3) heterozygous missense variants 
of unknown significance (VUS) and (4) heterozygous missense bystander variants.   
As a result, we have further defined the relationship between variants in the 
RTEL1 gene and this spectrum of disease. The initial disease association was made 
when biallelic RTEL1 variants were shown to cause early onset of a severe form of 
DC and HH.3,5,6,11 Here, we describe five new biallelic families (Figure 1A and 1B), 
where the variants are believed to be disease causing in four (Families 1-4). Two 
families presented with AA, two with DC and one with HH (Table 1 and Table S1). 
Interestingly, in one of these the index case presented with AA in adulthood. In the 
HH family (Family 5), we believe the homozygous RTEL1 variant is a bystander as it 
did not segregate with disease, being homozygous in both the index case, with 
severe disease in infancy, and in the asymptomatic 25 year old mother. 
Three disease causing heterozygous LOF RTEL1 variants (nonsense and 
frameshift deletion) were found in patients from four unrelated families (Figure 1B 
and 1C), one of whom presented with DC and the others with MDS and/or liver 
disease. Therefore, this extends the phenotypes associated with heterozygous loss 
of function RTEL1 variants to include late onset of MDS and liver disease (Figure 1C 
and Table 2). This combination of hematological and liver disease is very 
3 
 
 
reminiscent of that established for heterozygous variants in another telomere related 
gene, TERT12, which can also present with a severe early onset disease when the 
variants are biallelic.13  
The families we present clearly illustrate the variable penetrance of 
heterozygous RTEL1 variants. This is exemplified by Family 6 (Figure 1C, p.R1010*) 
where the index case had DC features, which did not become apparent until age 77 
years. His daughter had liver disease at age of 52 years, and segregation analysis 
identified four asymptomatic carriers aged below 50 years. This family highlights not 
only variable penetrance of heterozygous LOF variants but also suggests a late 
onset disease predisposition. The same RTEL1 variant was identified in Family 7 
(Figure 1C and Table 2), where it was associated with MDS and nail dystrophy in the 
45 year old index case.  Interestingly, this same variant is reported by Ballew et al6 in 
a heterozygous state as being the cause of HH in two siblings (aged three and one 
years) with very short telomeres. In that family, the mother also harboured the 
variant, had short telomeres but was asymptomatic. Indeed, in most of the families 
where the index case has disease due to biallelic RTEL1 variants, both here and in 
previous reports, the heterozygous parents are generally asymptomatic. However, 
we now note that these individuals may nevertheless be predisposed to developing 
disease in their later years. This is suggested by Family 2 (Figure 1A, p.G1096W) 
where there is a history of pulmonary disease in the grandmother in her 70s and for 
the p.R998* variant, which has been seen in both severe recessive3,5,6  and late 
onset dominant settings (Families 4 and 8 and Cogan et al7). Thus, it is important to 
be careful when counselling families.   
We have identified 14 unrelated patients (Table 1 and Table S2) with nine 
heterozygous missense variants we believe to be bystanders due to their occurrence 
at an allele frequency of more than 1 in 3,000 in the ExAC population. Additionally, 
12 unrelated patients with DC (n=5), AA (n=5), MDS (n=1) and AML (n=1) were 
found to harbour rare heterozygous missense variants. We have classified these as 
variants of unknown significance (VUS) as they are either not seen in the ExAC 
population or are present at an allele frequency of less than 1 in 10,000 (Table 1 and 
Table S2). The average CADD score for these VUS (average 15.43, range 0.001 – 
33), is lower compared to those that we believe to be disease-causing (average 
30.13, range 12.9 – 37, Table 1). We also note that of the 15 heterozygous RTEL1 
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variants previously reported to be associated with pulmonary disease2,7,8, eight of 
them are missense.  
We have measured telomere lengths by monochrome multiplex quantitative 
PCR14 in peripheral blood DNA from all patients bar one, which had poor DNA 
quality (Table 1 and Figure 1D). In agreement with previous studies reporting the 
impact of RTEL1 variants on telomere length, we observed that patients with biallelic 
variants and those with heterozygous loss of function variants had significantly 
shorter telomeres than controls as determined by the age-adjusted T/S ratio 
(p=0.0005 and p=0.003 respectively, 1 way ANOVA with Dunn’s multiple comparison 
test). The median age adjusted T/S ratio for the biallelic group is below the 1st centile 
(-0.6 compared with -0.54) and for the LOF group is below the 10th centile (-0.43 
compared with -0.34). It is interesting to note that for the VUS variants, there 
appears to be two subgroups. The lower four points correspond to p.G664V, 
p.P908R, p.R981W and p.T1377A. Three of these variants affect key domains within 
the protein and may impact on the function of RTEL1 (Figure 1B). These are the 
helicase C domain (G644V) and the harmonin domain (P908R and R981W).  
Previously we reported a recurrent missense variant p.R981W as a 
compound heterozygote in three young unrelated probands (under 12 years old) with 
HH.3 Here, we observed the same variant in a heterozygous state in a 24 year old 
patient with AA from a consanguineous family (patient 14 in Table 1 and Table S2). 
In this case, there is no strong evidence that this variant p.R981W is the cause of AA 
on account of the relatively high frequency of this variant in the ExAC population (6 
in 119930 alleles). However, we do note the short telomeres in this patient and the 
very high CADD score of this variant, indicating the possibility that it acts as a risk 
factor for disease.  
When a patient presents with an RTEL1 variant, a difficulty therefore arises as 
to whether or not it should be considered pathogenic, as there are a multitude of rare 
coding RTEL1 variants in the population at large. Using the ExAC database, the sum 
of number of very rare heterozygous coding alleles (at a frequency of <0.0001) is 
1,195 in an average of approximately 56,700 people. This is significantly lower than 
the number of very rare coding variants that we have identified in our cohort (22 in 
429 patients, Fisher’s exact test, P = 0.003), but on a case-by-case basis this 
background poses a problem. In addition to looking at the ExAC database for 
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population frequency there are several parameters that we have used to assign 
pathogenic status. The association of the rare variant with the pathology is a given, if 
the patient under review is presenting with one of the RTEL1 related disease 
features. Telomere length measurement is now widely used and our experience here 
is that the heterozygotes, who are often more elderly, may have telomere lengths 
that are short, but not necessarily very short. We have also looked at T-circles15, and 
shown that in some cases their presence is clearly increased where there is a loss of 
function variant compared to a common missense variant (Figure 1E). However, this 
test is not easy to perform and a normal range has not been established. The in 
silico prediction tools are helpful and improving, but remain a guide, and by no 
means a definitive test. Finally, the segregation of the variant with disease can be 
decisive. This is more often the case in exclusion rather than inclusion as we show in 
Family 5 (Figure 1A and Table S1).  
In summary, our study reports on several important observations. Firstly, 
heterozygous LOF RTEL1 variants are associated with myelodysplasia and liver 
disease in adulthood. Secondly, biallelic RTEL1 variants can present with just bone 
marrow failure in adulthood. Thirdly, many heterozygous variants and even some 
biallelic RTEL1 variants are bystanders. Therefore, in order to assign an accurate 
status to each RTEL1 variant, detailed clinical and laboratory studies are necessary. 
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Table 1. RTEL1 variants identified in 35 index cases 
 
 
 
 
Index Diagnosis Age 
(years) 
Sex Telomere 
length T/S ratio 
(percentile) 
DNA change Protein change ExAC frequency# CADD 
PHRED 
B
i
a
l
l
e
l
i
c
 
Likely pathogenic 
1 AA 36 F 0.46 (1st) c.2942G>A (homozygous) p.R981Q 1 in 119934  28.4 
2 AA 12 F 0.49 (<10th) c.3286G>T (homozygous) p.G1096W 1 in 118164 26.2 
3 DC 14 M 0.4   (<1st)  c.2300G>A (homozygous) p.R767Q NR 27.7 
4 DC 15 F 0.64 (<10th) c.2785_2787delCAG (heterozygous) p.Q929del NR 12.9 
          c.2992C>T (heterozygous) p.R998*    2 in 119914 (1 in 59,957) 37 
Bystander 5 HH  2 F 0.45 (<1st) c.1716C>G (homozygous) p.I572M NR 24.9 
H
e
t
e
r
o
z
y
g
o
u
s
 
LOF  
Likely pathogenic 
6 DC 77 M 0.5   (<10th) c.3028C>T      p.R1010*   10 in 119716 (1 in 11,972) 34 
7 MDS 45 F 0.47 (<10th) c.3028C>T       p.R1010*  10 in 119716 (1 in 11,972) 34 
8 MDS 55 M 0.73 (<50th) c.2992C>T        p.R998*   2 in 119914 (1 in 59,957) 37 
9 MDS 54 M 0.48 (<10th) c.3012_3028del p.Q1005Kfs*80 NR 34 
Unknown significance 
10 AML 23 F 1.14 (>50th) c.3464C>T p.T1155M 5 in 117408 (1 in 23,482) 12.94 
11 MDS 20 F 0.95 (<50th) c.2965G>C p.E989Q 3 in 119938 (1 in 39,980) 22 
12 DC 10 M 0.39 (<1st) c.2723C>G p.P908R 1 in 119146 0.001 
13 DC 24 M 0.99 (>50th) c.208C>T p.R70C 10 in 120456 (1 in 12,046) 25.3 
14 AA 24 F 0.65 (<10th) c.2941C>T p.R981W 6 in 119930 (1 in 19.988) 33 
15 AA 6 F 1.04 (>50th) c.2351C>T p.A784V 6 in 118274 (1 in 19,712) 2.88 
16 AA 28 F 1.56 (>90th) c.3595G>A p.G1199R 4 in 107372 (1 in 26,843) 5.246 
17 DC 8 F 0.98 (>90th) c.1603A>G p.I535V NR 9.212 
18 DC 18 M 0.95 (<50th) c.3430G>A p.V1144M NR 23.6 
19 AA 28 M 0.56 (<10th) c.4129A>G† p.T1377A      NR 1.406 
20 AA 10 F 1.01 (>50th) c.3608G>A p.S1203N NR 23.5 
21 DC 16 F 0.47 (<10th) c.1991G>T p.G664V NR 26.1 
 Bystander 
22 DC 18 M 1.21 (>50th) c.2618G>A p.G873D  249 in 19124 (1 in 77) 10.29 
23 DC 37 M 0.64 (<10th) c.2516G>T p.S839I 126 in 71024 (1 in 564) 17.05 
24 AA 4 F 1      (>50th) c.3047C>T   p.P1016L  184 in 119184 (1 in 648) 10.85 
25 DC 50 F 0.94 (<50th) c.3047C>T  p.P1016L  184 in 119184 (1 in 648) 10.85 
26 DC NA M NA    c.3047C>T  p.P1016L  184 in 119184 (1 in 648) 10.85 
27 MDS/AML 61 F 0.63 (<10th) c.3128A>G p.Q1043R 151 in 118626 (1 in 786) 0.276 
28 DC 4 M 0.85 (<50th) c.3992G>A† p.R1331Q     120 in 101400 (1 in 845) 12.7 
29 DC 3 M 1.51 (>90th) c.3992G>A†    p.R1331Q   120 in 101400 (1 in 845) 12.7 
30 HH 0 M 0.69 (<50th) c.2734G>C p.V912L 85 in 117986 (1 in 1,388) 6.325 
31 DC 54 M 0.47 (<10th) c.4159C>T†     p.P1387S   71 in 110950 (1 in 1,563) 24.7 
32 AA 7 M 1.34 (>50th) c.4159C>T†    p.P1387S    71 in 110950 (1 in 1,563) 24.7 
33 DC 31 M 0.64 (<10th) c.1261C>G       p.Q421E  71 in 120318 (1 in 1,695) 24.2 
34 AA 34 M 0.6   (<10th) c.1261C>G     p.Q421E    71 in 120318 (1 in 1,695) 24.2 
35 DC 3 M 1.44 (>50th) c.3121G>A   p.D1041N  43 in 118650 (1 in 2,759) 14.34 
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NR: not reported; CADD PHRED: combined annotation dependent depletion score; AA: aplastic anemia; AML: acute myeloid leukemia; DC: dyskeratosis congenita; HH: 
Hoyeraal Hreidarsson syndrome; MDS: myelodysplasia. †variant is not in the canonical transcript ENST00000508582 seen in ExAC, but is found in ENST00000482936. 
Centiles for T/S ratios, established from a healthy control population (n = 202) are as follows: 99th centile = 1.99, 90th centile = 1.47, 50th centile = 0.96, 10th centile = 0.68, 1st 
centile = 0.46. Telomeres are considered short if they are at or below the 10th centile, and very short if they are at or below the 1st centile. 
#: For each of the rare variants reported (less than 10 heterozygotes), the ethnicity of our patient matched at least one reported on the ExAC.  
NB: Six index cases harbour variants in other known disease genes: index cases 11, 15, 28, 31, 33 and 35 harbour variants in TERT (heterozygous c.3197C>T; p.P1066L and 
c.322C>T; p.R108C), DNAJC21 (homozygous c.793G>T; p.Q265*), TERT (heterozygous c.1336_1337insC; p.R446Pfs93* and c.329G>C; p.G110A), TERT (homozygous 
c.3150G>C; p.K1050N) and TERC (heterozygous c.205C>T), TINF2 (heterozygous c.838A>G; p.K280Q), and DKC1 (hemizygous c.941A>C; p.K314T), respectively.   
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Table 2. Characteristics of families with RTEL1 LOF variants 
Family Individuals Age at study 
(years) 
Gender Clinical status Nucleotide Amino acid Variant status Clinical features/diagnosis 
6 I-1 NA F asymptomatic NA NA NA None 
 I-2 NA M asymptomatic NA NA NA None 
 II-1 NA F asymptomatic NA NA NA None 
 II-2 77 M affected c.3028C>T p.R1010*    Heterozygous DC, lacy skin pigmentation, pancytopenia, 
pulmonary fibrosis, cirrhosis 
 II-3 NA F asymptomatic NA NA NA None 
 III-1 NA M asymptomatic NA NA NA None 
 III-2 54 F asymptomatic c.3028C>T p.R1010*    Heterozygous None 
 III-3 52 F affected c.3028C>T p.R1010*    Heterozygous Liver disease (non-specific hepatitic changes) 
 III-4 49 F asymptomatic Wild type Wild type Wild type None 
 III-5 47 M asymptomatic c.3028C>T p.R1010*    Heterozygous None 
 III-6 NA F asymptomatic NA NA NA None 
 IV-1 20 F asymptomatic Wild type Wild type Wild type None 
 IV-2 17 F asymptomatic Wild type Wild type Wild type None 
 IV-3 16 F asymptomatic c.3028C>T p.R1010*    Heterozygous None 
 IV-4 23 F asymptomatic Wild type Wild type Wild type None 
 IV-5 21 F asymptomatic Wild type Wild type Wild type None 
 IV-6 7 F asymptomatic c.3028C>T p.R1010*    Heterozygous None 
 IV-7 4 M asymptomatic Wild type Wild type Wild type None 
7 I-1 NA F NA NA NA NA NA 
 I-2 NA M NA NA NA NA NA 
 III-1 45 F affected c.3028C>T p.R1010*    Heterozygous MDS, nail dystrophy 
8 I-1 NA F asymptomatic NA NA NA None 
 I-2 NA M asymptomatic NA NA NA None 
 II-1 55 M affected c.2992C>T p.R998* Heterozygous MDS (low risk), cirrhosis  
 II-2 47 M affected c.2992C>T p.R998* Heterozygous MDS (low risk), cirrhosis 
 II-3 NA F asymptomatic NA NA NA None 
9 I-1 46 F affected NA NA NA Liver and lung disease  
 I-2 NA M asymptomatic NA NA NA None 
 II-1 NA M asymptomatic NA NA NA None 
 II-2 NA F asymptomatic NA NA NA None 
 III-1 NA F asymptomatic NA NA NA None 
 III-2 54 M affected c.3012_3028del p.E1005Kfs*80 Heterozygous MDS (low risk), interstitial lung disease, cirrhosis, 
osteoporosis, baldness and psoriatiform skin  
 III-3 49 F asymptomatic Wild type Wild type Wild type None 
 IV-1 32 F asymptomatic c.3012_3028del p.E1005Kfs*80 Heterozygous None 
  IV-2 30 F asymptomatic Wild type Wild type Wild type None 
 
DC: dyskeratosis congenita; MDS: myelodysplasia; NA: not available; F: female; M: male.  
11 
 
 
Figure legends 
Figure 1. The segregation, location and impact of RTEL1 variants. (A) Families with 
biallelic RTEL1 variants and sequencing traces of index cases (homozygous, 
Families 1, 2, 3 and 5; compound heterozygous, Family 4). The genotyping is 
described as follows: wild-type (+/+), heterozygous (+/-) or biallelic (-/-). The age at 
study is given in years. Affected individuals are coloured in black. NA: not available. 
(B) RTEL1 protein (NP_116575.3) schematic showing in blue the location of the 
biallelic variants and in red the heterozygous LOF variants. Conserved protein 
domains include the P-loop NTPase (yellow); the Rad3 domain (green) that includes 
the DEAD2 domain (red) and the Helicase C-terminal domain (purple); Harmonin N-
like domain (blue); PIP-box – the proliferating cell nuclear antigen interacting protein 
domain (black). (C) Families with heterozygous LOF RTEL1 variants and sequencing 
traces of index cases, annotated as in panel A. (D) Age adjusted telomere length 
values (delta-tel) were measured by subtracting the observed T/S ratio from the 
expected T/S ratio, using the equation derived from the line of best fit through the 
plot of T/S ratios from healthy control samples against age. Patients with TERC 
variants are included as a group with known short telomeres. Centiles were 
calculated from the control delta-tel values as follows: 99th centile = 0.95, 90th centile 
= 0.42, 50th centile = 0.06, 10th centile = -0.34, 1st centile = -0.54. The different 
genotypes are represented as follows, TERC-circles (n=44); biallelic-squares (n=5); 
loss of function (LOF)-triangles (n=6); variants of unknown significance (VUS)-
diamonds (n=12); bystanders-inverted triangles (n=13); controls-grey squares 
(n=202). (E) T-circle amplification using Phi29 polymerase detected by Southern blot 
analysis. Samples: p.R70C - patient with sporadic DC carrying this variant of 
unknown significance (patient 13 in Table 1); p.R998* - proband of Family 8 carrying 
this LOF variant (Table 1); positive control - genomic DNA extracted from WI-38 VA-
13 cells, known to produce T-circle.
 

Table S1. Characteristics of families with biallelic RTEL1 variants 
Family Individuals Age at 
study  
(years) 
Gender Clinical status Nucleotide Amino acid Variant status Clinical features/diagnosis 
1 I-1 NA F asymptomatic NA NA NA None 
 I-2 NA M asymptomatic NA NA NA None 
 II-1 NA M asymptomatic NA NA NA None 
 II-2 36 F affected c.2942G>A p.R981Q    Homozygous AA; short stature 
2 I-1 70 F affected NA NA NA Pulmonary fibrosis 
 I-2 NA M NA NA NA NA NA 
 II-1 40 F asymptomatic c.3286G>T p.G1096W    Heterozygous None 
 II-2 43 M asymptomatic c.3286G>T p.G1096W    Heterozygous None 
 III-1 16 F asymptomatic NA NA NA None 
 III-2 15 F asymptomatic NA NA NA None 
 III-3 12 F affected c.3286G>T p.G1096W    Homozygous AA, pulmonary fibrosis, corrugated tongue 
 III-4 3 M affected c.3286G>T p.G1096W    Homozygous AA 
3 I-1 40 F asymptomatic c.2300G>A p.R767Q    Heterozygous None 
 I-2 37 M asymptomatic c.2300G>A p.R767Q    Heterozygous None 
 II-1 15 M asymptomatic NA NA NA None 
 II-2 14 M affected c.2300G>A p.R767Q    Homozygous DC, blepharitis, conjunctivitis, pancytopenia, atrial septal 
defect, low birth weight, growth restriction 
 II-3 13 M asymptomatic NA NA NA None 
 II-4 12 F asymptomatic NA NA NA None 
 II-5 10 M asymptomatic NA NA NA None 
 II-6 8 M asymptomatic c.2300G>A p.R767Q    Heterozygous None 
 II-7 5 M asymptomatic NA NA NA None 
4 I-1 46 F asymptomatic c.2785_2787delCAG p.Q929del Heterozygous None 
 I-2 50 M asymptomatic c.2992C>T p.R998* Heterozygous None 
 II-1 24 F asymptomatic c.2992C>T p.R998* Heterozygous None 
 II-2 15 F affected c.2785_2787delCAG  p.Q929del  Compound heterozygous DC 
     c.2992C>T p.R998*  
5 I-1 25 F asymptomatic c.1716C>T p.I572M Homozygous None 
 I-2 31 M asymptomatic c.1716C>T p.I572M Heterozygous None 
 II-1 still birth M NA NA NA NA NA 
 II-2 Still birth M NA NA NA NA NA 
 II-3 6 weeks NA affected NA NA NA Turner syndrome 
 II-4 2 F affected c.1716C>T p.I572M Homozygous HH 
 II-5 NA F NA NA NA NA NA 
 
AA: aplastic anemia; DC: dyskeratosis congenita; HH: Hoyeraal Hreidarsson syndrome; NA: not available; F: female; M: male.   
 
 
 
 
AML: acute myeloid leukemia; MDS: myelodysplasia; DC: dyskeratosis congenita; AA: aplastic anemia; HH: Hoyeraal Hreidarsson syndrome; BMF: bone marrow failure; NA: not 
available; F: female; M: male.   
 
 
 Table S2. Characteristics of index cases with heterozygous VUS and bystander RTEL1 variants 
 Index 
 
Age at study  
(years) 
Gender Diagnosis Additional relevant clinical features 
U
n
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10 23 F AML Short stature 
11 20 F MDS Skin pigmentation abnormality and squamous cell carcinoma of oesophagus. This patient harbours variants in TERT (heterozygous 
c.3197C>T; p.P1066L and c.322C>T; p.R108C) 
12 10 M DC Developmental delay, short stature, dysmorphic facial features, microcephaly, BMF and pulmonary disease 
13 24 M DC Skin pigmentation abnormality, leukoplakia, thin hair and BMF 
14 24 F AA  
15 6 F AA Short stature and oral ulceration with dysphagia. This patient harbours variant in DNAJC21 (homozygous c.793G>T; p.Q265*) 
16 28 F AA  
17 8 F DC Nail dystrophy and leukoplakia 
18 18 M DC Skin pigmentation abnormality, thin hair, extensive dental caries and BMF 
19 28 M AA  
20 10 F AA  
21 16 F DC Skin pigmentation abnormality, nail dystrophy, leukoplakia, small teeth, sparse scalp hair, epiphora, microcephaly and BMF 
B
y
s
ta
n
d
e
r 
22 18 M DC Skin pigmentation abnormality, nail dystrophy, hair loss, extensive dental caries, developmental delay and short stature 
23 37 M DC Skin pigmentation abnormality, nail dystrophy, hair loss, frequent otitis, mild hearing loss and extensive caries/ dental loss                       
24 4 F AA  
25 50 F DC Nail dystrophy, cirrhosis, duodenal ulcers, deafness and developmental delay 
26 NA M DC Skin pigmentation abnormality, nail dystrophy, leucoplakia and leukemia 
27 61 F MDS/AML  
28 4 M                                                                                                                                      DC Skin pigmentation abnormality, nail dystrophy, microcephaly, low birthweight, developmental delay and cerebellar atrophy. This 
patient harbours variants in TERT (heterozygous c.1336_1337insC; p.R446Pfs93* and c.329G>C; p.G110A) 
29 3 M DC Skin pigmentation abnormality, nail dystrophy, abnormal facies, microcephaly, ear abnormality and difficulty in swallowing 
30 0 M HH Congenital cytomegalovirus infection, microcephaly, generalized seizures, intracranial calcifications, growth restriction, low birth 
weight and BMF 
31 54 M DC Skin pigmentation abnormality, nail dystrophy, hair loss, tooth loss, renal failure and BMF. This patient harbours variants in TERT 
(homozygous c.3150G>C; p.K1050N) and TERC (heterozygous c.205C>T) 
32 7 M AA  
33 31 M DC Skin pigmentation abnormality, leukoplakia, epiphora, duodenal ulcers, cirrhosis, hepato-pulmonary syndrome and BMF. This 
patient harbours variant in TINF2 (heterozygous c.838A>G; p.K280Q) 
34 34 M AA  
35 3 M DC Skin pigmentation abnormality, nail dystrophy, leucoplakia, hair loss, microcephaly, premature birth with intrauterine growth 
restriction, glaucoma, premature aging, malabsorption, developmental delay and BMF. This patient harbours variant in DKC1 
(hemizygous c.941A>C; p.K314T) 
